RU2000129666A - STABLE MITOXANTRON SOLUTIONS - Google Patents

STABLE MITOXANTRON SOLUTIONS

Info

Publication number
RU2000129666A
RU2000129666A RU2000129666/14A RU2000129666A RU2000129666A RU 2000129666 A RU2000129666 A RU 2000129666A RU 2000129666/14 A RU2000129666/14 A RU 2000129666/14A RU 2000129666 A RU2000129666 A RU 2000129666A RU 2000129666 A RU2000129666 A RU 2000129666A
Authority
RU
Russia
Prior art keywords
sodium
mitoxantrone
solution
acetic acid
sodium edetate
Prior art date
Application number
RU2000129666/14A
Other languages
Russian (ru)
Other versions
RU2219917C2 (en
Inventor
Катрин МОШНЕР
Марио Вайнгарт
Михель Пирот
Вольфганг МОРИК
Элизабет ВОЛЬФ-ХОЙСС
Original Assignee
Арцнаймиттельверк Дрезден Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19818802A external-priority patent/DE19818802A1/en
Application filed by Арцнаймиттельверк Дрезден Гмбх filed Critical Арцнаймиттельверк Дрезден Гмбх
Publication of RU2000129666A publication Critical patent/RU2000129666A/en
Application granted granted Critical
Publication of RU2219917C2 publication Critical patent/RU2219917C2/en

Links

Claims (7)

1. Стабильные растворы митоксантрона, содержащие 1-5 мг гидрохлорида митоксантрона/мл раствора, 0,001-0,15% эдетата натрия и в качестве других составных частей хлористый натрий, уксуснокислый натрий и уксусную кислоту.1. Stable solutions of mitoxantrone containing 1-5 mg of mitoxantrone hydrochloride / ml solution, 0.001-0.15% sodium edetate and, as other components, sodium chloride, sodium acetic acid and acetic acid. 2. Стабильные растворы митоксантрона для инъекций по п. 1, отличающиеся тем, что содержание эдетата натрия предпочтительно составляет 0,04%. 2. Stable solutions of mitoxantrone for injection according to claim 1, characterized in that the content of sodium edetate is preferably 0.04%. 3. Способ получения стабильных растворов митоксантрона по пп. 1 и 2, отличающийся тем, что хлористый натрий, уксуснокислый натрий, уксусную кислоту и эдетат натрия растворяют в обедненной кислородом воде, в часть раствора вводят гидрохлорид митоксантрона, растворы объединяют и доводят до конечного объема с содержанием 1-5 мг гидрохлорида митоксантрона/мл раствора и 0,001-0,15% эдетата натрия/мл раствора. 3. The method of obtaining stable solutions of mitoxantrone according to paragraphs. 1 and 2, characterized in that sodium chloride, sodium acetic acid, acetic acid and sodium edetate are dissolved in oxygen-depleted water, mitoxantrone hydrochloride is introduced into part of the solution, the solutions are combined and adjusted to a final volume with a content of 1-5 mg of mitoxantrone hydrochloride / ml of solution and 0.001-0.15% sodium edetate / ml solution. 4. Способ по п. 3, отличающийся тем, что добавляют предпочтительно 0,04% эдетата натрия. 4. The method according to p. 3, characterized in that preferably add 0.04% sodium edetate. 5. Стабильные растворы митоксантрона по п. 1 для получения лекарственного средства, применяемого при раковых заболеваниях. 5. Stable solutions of mitoxantrone according to claim 1 for the manufacture of a medicament used for cancer. 6. Лекарственное средство, применяемое при раковых заболеваниях, отличающееся тем, что оно содержит 1-5 мг гидрохлорида митоксантрона/мл раствора, эдетат натрия в количестве 0,001-0,15% в расчете на раствор гидрохлорида митоксантрона и в качестве других составных частей хлористый натрий, уксуснокислый натрий и уксусную кислоту. 6. A medicine used for cancer, characterized in that it contains 1-5 mg of mitoxantrone hydrochloride / ml of solution, sodium edetate in an amount of 0.001-0.15% per solution of mitoxantrone hydrochloride and as other components sodium chloride , sodium acetate and acetic acid. 7. Лекарственное средство по п. 6, отличающееся тем, что оно содержит предпочтительно 0,04% эдетата натрия. 7. The drug according to claim 6, characterized in that it preferably contains 0.04% sodium edetate.
RU2000129666/14A 1998-04-27 1999-04-01 Mitoxantrone stable solution RU2219917C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19818802A DE19818802A1 (en) 1998-04-27 1998-04-27 Stable mitoxantron solutions useful for cancer therapy
DE19818802.1 1998-04-27

Publications (2)

Publication Number Publication Date
RU2000129666A true RU2000129666A (en) 2002-10-10
RU2219917C2 RU2219917C2 (en) 2003-12-27

Family

ID=7865948

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000129666/14A RU2219917C2 (en) 1998-04-27 1999-04-01 Mitoxantrone stable solution

Country Status (18)

Country Link
US (1) US6143795A (en)
EP (1) EP1073469B1 (en)
JP (1) JP2002512981A (en)
CN (1) CN1195548C (en)
AR (1) AR018198A1 (en)
AT (1) ATE282431T1 (en)
AU (1) AU744502B2 (en)
BG (1) BG64767B1 (en)
BR (1) BR9909981A (en)
CA (1) CA2270004C (en)
CO (1) CO5021217A1 (en)
DE (2) DE19818802A1 (en)
HK (1) HK1036012A1 (en)
HU (1) HUP0102075A3 (en)
NZ (1) NZ507407A (en)
RU (1) RU2219917C2 (en)
TW (1) TWI224003B (en)
WO (1) WO1999055375A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
ES2528669T3 (en) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
CN102397561B (en) * 2011-09-26 2013-03-06 沈阳药科大学 Application of mitoxantrone as lymph tracer
JP5589110B1 (en) * 2013-03-08 2014-09-10 株式会社ポーラファルマ Crystal having crystal habit and pharmaceutical composition containing the crystal as an active ingredient
CN107149592B (en) * 2017-06-23 2019-10-08 沈阳天邦药业有限公司 Biological self-assembly nano-crystalline injection and preparation method with lympha targeted function
CN113730603B (en) * 2020-05-27 2023-01-24 深圳华润九创医药有限公司 Application of mitoxantrone preparation in preparation of medicine for treating thyroidectomy-related diseases
CN114601791B (en) * 2020-12-08 2023-09-19 成都倍特药业股份有限公司 Mitoxantrone hydrochloride liquid preparation and preparation method thereof
CN114732807A (en) * 2022-03-27 2022-07-12 苏州大学 Application of mitoxantrone in the preparation of drugs for preventing or treating acute graft-versus-host disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3248291A (en) * 1963-08-19 1966-04-26 Hoffmann La Roche Stabilized thioxanthene derivatives and method of using the same
EP0236822B1 (en) * 1986-03-07 1990-12-27 American Cyanamid Company Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
DE3825374A1 (en) * 1988-07-26 1990-02-01 Schwendener Reto Dipl Apotheke Complex of at least one lipophilic acid and mitoxantrone and/or bisantrene
AU5680994A (en) * 1992-12-10 1994-07-04 Abbott Laboratories Stabilized catecholamine solutions
FR2758264B1 (en) * 1997-01-16 1999-03-26 Charles Dumontet DRUG COMPOSITIONS CONTAINING EDTA OR A DERIVATIVE THEREOF FOR THE PREVENTION OF SKIN TOXICITY AND SUBCUTANEOUS ANTHRACYCLINES AND DERIVATIVES THEREOF

Similar Documents

Publication Publication Date Title
KR101715008B1 (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
US4778810A (en) Nasal delivery of caffeine
IE59055B1 (en) Effervescent composition with analgesic activity
US5047398A (en) DDAVP antidiuretic and method therefor
EA200700389A1 (en) STABLE FOR STORAGE INFUSION SOLUTION OF DIHYDROPTERIDINONES
MY102459A (en) Oral sustained release pharmaceutical preparation.
EP2453743B1 (en) N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
JPS6245535A (en) Acylcarnitines as absorption enhancer for supplying drug through mucosa of nose, mouth, tongue and vagina
RU2000129666A (en) STABLE MITOXANTRON SOLUTIONS
DK342989D0 (en) Anti-inflammatory drug
CA2425218A1 (en) Pharmaceutical solutions of modafinil compounds
RU2006120946A (en) COMPOSITION OF PREGABALIN
CN102264346A (en) Formulations for administration of hypolipidemic agents by buccal transmucosal route
US4892877A (en) Antitussive liquid compositions containing phenol
CO5021217A1 (en) STABLE COMPOSITIONS OF MITOXANTRONE, PROCEDURE TO PREPARE THEM; USE OF SUCH COMPOSITIONS AND MEDICATIONS THAT INCLUDE SUCH SOLUTIONS FOR THE TREATMENT OF CANCER DISEASES
WO2002036101A1 (en) Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications
WO2000026185A3 (en) Omeprazole solution and method of using same
RU2005113980A (en) STRENGTHENING ALCOHOL METABOLISM
JP2001505222A (en) Topical formulation for introducing peptide drugs into organisms
RU96109524A (en) COMPOSITION - MEDICINAL FORM OF ANTI-ARTISTIC MEANS OF GLUCOSAMINE HYDROCHLORIDE FOR INJECTION
JP2004269363A (en) Stable aqueous medicinal composition comprising acetaminophen
RU2001124532A (en) A method for the treatment of nephrolithiasis
Uwiera et al. Liposomes targeted to deliver antisecretory agents to jejunal mucosa.
RU97109804A (en) METHOD OF ANESTHESIA
RU2001135039A (en) A method for the prevention of acute pyelonephritis in patients with urolithiasis